| Preview | Issue Date | Title | Author(s) |
| 1999 | A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. | Wolff, K.; Farrell, M.; Marsden, J.; Monteiro, M.; Ali, R.; Welch, S.; Strang, J. |
| 2009 | Alpha₂-adrenergic agonists for the management of opioid withdrawal | Gowing, L.; Farrell, M.; Ali, R.; White, J.; Gowing, L. |
| 2002 | a₂-Adrenergic agonists in opioid withdrawal | Gowing, L.; Farrell, M.; Ali, R.; White, J. |
| 2011 | Cochrane systematic reviews in the field of addiction: what's there and what should be | Amato, L.; Davoli, M.; Vecchi, S.; Ali, R.; Farrell, M.; Faggiano, F.; Foxcroft, D.; Ling, W.; Minozzi, S.; Chengzheng, Z. |
| 2004 | Cochrane systematic reviews: time for an introduction and appraisal | Ling, W.; Farrell, M.; Ali, R. |
| 2005 | Effectiveness of drug dependence treatment in HIV prevention | Farrell, M.; Gowing, L.; Marsden, J.; Ling, W.; Ali, R. |
| 2015 | Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol | Degenhardt, L.; Larance, B.; Bruno, R.; Lintzeris, N.; Ali, R.; Farrell, M. |
| 2022 | Examining the cost and impact of dosing fees among clients in opioid agonist treatment: results from a cross-sectional survey of Australian treatment clients | Zahra, E.; Chen, R.; Nielsen, S.; Tran, A.D.; Santo, T.; Degenhardt, L.; Farrell, M.; Byrne, J.; Ali, R.; Larance, B. |
| 2018 | Global statistics on alcohol, tobacco and illicit drug use: 2017 status report | Peacock, A.; Leung, J.; Larney, S.; Colledge, S.; Hickman, M.; Rehm, J.; Giovino, G.A.; West, R.; Hall, W.; Griffiths, P.; Ali, R.; Gowing, L.; Marsden, J.; Ferrari, A.J.; Grebely, J.; Farrell, M.; Degenhardt, L. |
| 1996 | Heroin overdose: the case for take-home naltrexone | Strang, J.; Darke, S.; Hall, W.; Farrell, M.; Ali, R. |
| 2004 | HIV in injecting drug users in Asian countries | Wodak, A.; Ali, R.; Farrell, M. |
| 2005 | HIV in injecting drug users in Asian countries - Reply | Wodak, A.; Ali, R.; Farrell, M. |
| 2012 | Maintenance drugs to treat opioid dependence | Farrell, M.; Wodak, A.; Gowing, L. |
| 2006 | Methadone treatment of injecting opioid users for prevention of HIV infection | Gowing, L.; Farrell, M.; Bornemann, R.; Sullivan, L.; Ali, R. |
| 2011 | Oral substitution treatment of injecting opioid users for prevention of HIV infection (Review) | Gowing, L.; Farrell, M.; Bornemann, R.; Sullivan, L.; Ali, R. |
| 2021 | Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes | Jones, N.R.; Nielsen, S.; Farrell, M.; Ali, R.; Gill, A.; Larney, S.; Degenhardt, L. |
| 2008 | Substitution treatment of injecting opioid users for prevention of HIV infection | Gowing, L.; Farrell, M.; Bornemann, R.; Sullivan, L.; Ali, R.; Gowing, L. |
| 2002 | The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility | Ali, R.; Awwad, E.; Babor, T.; Bradley, F.; Butau, T.; Farrell, M.; Formigoni, M.; Isralowitz, R.; Boerngen de Lacerda, R.; Marsden, J.; McRee, B.; Monteiro, M.; Pal, H.; Rubio-Stipec, M.; Vendetti, J.; Ali, Robert Leonard |
| 2008 | Validation of the alcohol, smoking and substance involement screening test (ASSIST) | Humeniuk, R.; Ali, R.; Babor, T.; Farrell, M.; Formigoni, M.; Jittiwutikarn, J.; Boerngen de Lacerda, R.; Ling, W.; Marsden, J.; Monteiro, M.; Nhiwatiwa, S.; Pal, H.; Poznyak, V.; Simon, S. |
